apraclonidine (iopidine) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Apraclonidine (IOPIDINE) is an α2-adrenergic receptor agonist and a weak α1-adrenergic receptor agonist. It is used for the prevention and treatment of postsurgical intraocular pressure elevation. The following adverse events, occurring in less than 2% of patients, were reported in association with the use of IOPIDINE Ophthalmic Solution in laser surgery: ocular injection, upper lid elevation, irregular heart rate, nasal decongestion, ocular inflammation, conjunctival blanching, and mydriasis. Interactions with other agents have not been investigated.   NCATS

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$2.1250 - $27.2821

Australia

$19.4290
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-(4-amino-2,6-dichloro)phenyliminoimidazolidine | 4-aminoclonidine | al-02145 | alo 2145 | alo-2145 | aminoclonidine monohydrochloride | aplonidine | aplonidine hcl | apraclonidina | apraclonidine | apraclonidine hcl | apraclonidine hydrochloride | apraclonidinum | iopidine | iopidine 1% | iopimax | lopidine | p-aminoclonidine | para-aminoclonidine

Organizations (7)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (1)


 

Ocular Hypertension (approved 1987)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Facial Nerve Injuries (Phase 4)

Myasthenia Gravis (Phase 2)

Synkinesis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue